No Data
No Data
Bullish BioCryst Pharmaceuticals Insiders Loaded Up On US$1.05m Of Stock
BioCryst Pharmaceuticals' Hereditary Angioedema Drug Gets Recommendation From Ireland Regulator
BioCryst Launches ORLADEYO (Berotralstat) in Ireland
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating
BioCryst (BCRX) Receives a Buy From Bank of America Securities
When Will BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Become Profitable?
No Data